A citation-based method for searching scientific literature

Frederick Arce Vargas, Andrew J S Furness, Kevin Litchfield, Kroopa Joshi, Rachel Rosenthal, Ehsan Ghorani, Isabelle Solomon, Marta H Lesko, Nora Ruef, Claire Roddie, Jake Y Henry, Lavinia Spain, Assma Ben Aissa, Andrew Georgiou, Yien Ning Sophia Wong, Myles Smith, Dirk Strauss, Andrew Hayes, David Nicol, Tim O'Brien, Linda Mårtensson, Anne Ljungars, Ingrid Teige, Björn Frendéus, Martin Pule, Teresa Marafioti, Martin Gore, James Larkin, Samra Turajlic, Charles Swanton, Karl S Peggs, Sergio A Quezada. Cancer Cell 2018
Times Cited: 305







List of co-cited articles
1436 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, Welby Montalvo-Ortiz, Manuel A Sepulveda, Katharina Bergerhoff, Frederick Arce, Claire Roddie, Jake Y Henry, Hideo Yagita, Jedd D Wolchok,[...]. J Exp Med 2013
928
33

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, Michael Quigley, Karla A Henning, Timothy Chen, Mohan Srinivasan, Alan J Korman. Cancer Immunol Res 2013
559
25

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, Periklis G Foukas, Petra Baumgaertner, Christiane Meyer, Pierluigi Ballabeni, Olivier Michielin, Benjamin Weide, Pedro Romero, Daniel E Speiser. Proc Natl Acad Sci U S A 2015
374
25

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
23

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
19

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, Jorge Blando, Jorge Scutti, Luis Vence, Jennifer Wargo, James P Allison, Antoni Ribas, Padmanee Sharma. Clin Cancer Res 2019
164
15


A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, Mingyue Liu, Juanjuan Su, Yan Zhang, Wei Wu, Martin Devenport, Christopher A Lazarski, Peng Zhang, Xu Wang,[...]. Cell Res 2018
123
14

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, Maurice Windman, Sarah M Rue, Seth Ettenberg, Deborah A Knee, Nicholas S Wilson, Glenn Dranoff, Jennifer L Brogdon. J Exp Med 2013
325
14

Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison. Science 1996
13

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Takahiro Kamada, Yosuke Togashi, Christopher Tay, Danbee Ha, Akinori Sasaki, Yoshiaki Nakamura, Eiichi Sato, Shota Fukuoka, Yasuko Tada, Atsushi Tanaka,[...]. Proc Natl Acad Sci U S A 2019
375
12

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey, Christopher D Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski,[...]. N Engl J Med 2015
12

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
11

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
11

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
11

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
11

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas. Cell 2017
11

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
10

CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, C Y Bakker, P S Linsley, G J Freeman, J M Green, C B Thompson, J A Bluestone. Immunity 1994
10

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
Enfu Hui, Jeanne Cheung, Jing Zhu, Xiaolei Su, Marcus J Taylor, Heidi A Wallweber, Dibyendu K Sasmal, Jun Huang, Jeong M Kim, Ira Mellman,[...]. Science 2017
759
10

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
10

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Danbee Ha, Atsushi Tanaka, Tatsuya Kibayashi, Atsushi Tanemura, Daisuke Sugiyama, James Badger Wing, Ee Lyn Lim, Karen Wei Weng Teng, Dennis Adeegbe, Evan W Newell,[...]. Proc Natl Acad Sci U S A 2019
84
11

CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, Paz Prieto-Martin, Tomoyuki Yamaguchi, Makoto Miyara, Zoltan Fehervari, Takashi Nomura, Shimon Sakaguchi. Science 2008
10

Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.
George Plitas, Catherine Konopacki, Kenmin Wu, Paula D Bos, Monica Morrow, Ekaterina V Putintseva, Dmitriy M Chudakov, Alexander Y Rudensky. Immunity 2016
330
10

The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken. Nat Rev Immunol 2018
682
10

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
9

B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez, Aurélien de Reyniès, Emily Z Keung, Tom Wei-Wu Chen, Cheng-Ming Sun, Julien Calderaro, Yung-Ming Jeng, Li-Ping Hsiao, Laetitia Lacroix, Antoine Bougoüin,[...]. Nature 2020
607
9

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, Cynthia A Chambers, Alan J Korman, James P Allison. J Exp Med 2009
625
9

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, Alexandria P Cogdill, Yang Zhao, Nana-Ama A S Anang, Miles C Andrews, Padmanee Sharma, Jing Wang, Jennifer A Wargo, Dana Pe'er,[...]. Cell 2017
655
9

Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho,[...]. N Engl J Med 2014
9

Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
Yosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa. Nat Rev Clin Oncol 2019
444
9

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
8

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
8

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P M Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P Roberti,[...]. Science 2018
8

B cells and tertiary lymphoid structures promote immunotherapy response.
Beth A Helmink, Sangeetha M Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar, Rohit Thakur, Keren Yizhak, Moshe Sade-Feldman, Jorge Blando, Guangchun Han,[...]. Nature 2020
699
8

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.
Omar S Qureshi, Yong Zheng, Kyoko Nakamura, Kesley Attridge, Claire Manzotti, Emily M Schmidt, Jennifer Baker, Louisa E Jeffery, Satdip Kaur, Zoe Briggs,[...]. Science 2011
967
8

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
8

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
8


Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, Marcel P Trefny, Seth Garren, Cécile Piot, Camilla Engblom, Christina Pfirschke, Marie Siwicki, Jeremy Gungabeesoon,[...]. Immunity 2018
392
8

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, Eri Sugiyama, Hitomi Nishinakamura, Yoshiko Takeuchi, Kochin Vitaly, Kota Itahashi, Yuka Maeda, Shigeyuki Matsui,[...]. Nat Immunol 2020
167
8

Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber. Science 2015
8

Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Jessica R Ingram, Olga S Blomberg, Mohammad Rashidian, Lestat Ali, Scott Garforth, Elena Fedorov, Alexander A Fedorov, Jeffrey B Bonanno, Camille Le Gall, Stephanie Crowley,[...]. Proc Natl Acad Sci U S A 2018
83
9

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, Heiko Schuster, Etienne Caron, Jeffrey P Ward, Takuro Noguchi, Yulia Ivanova, Jasreet Hundal, Cora D Arthur, Willem-Jan Krebber,[...]. Nature 2014
7

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Marie Vétizou, Jonathan M Pitt, Romain Daillère, Patricia Lepage, Nadine Waldschmitt, Caroline Flament, Sylvie Rusakiewicz, Bertrand Routy, Maria P Roberti, Connie P M Duong,[...]. Science 2015
7

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.
Imran Siddiqui, Karin Schaeuble, Vijaykumar Chennupati, Silvia A Fuertes Marraco, Sandra Calderon-Copete, Daniela Pais Ferreira, Santiago J Carmona, Leonardo Scarpellino, David Gfeller, Sylvain Pradervand,[...]. Immunity 2019
474
7

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Brian C Miller, Debattama R Sen, Rose Al Abosy, Kevin Bi, Yamini V Virkud, Martin W LaFleur, Kathleen B Yates, Ana Lako, Kristen Felt, Girish S Naik,[...]. Nat Immunol 2019
552
7

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.
Jan P Böttcher, Eduardo Bonavita, Probir Chakravarty, Hanna Blees, Mar Cabeza-Cabrerizo, Stefano Sammicheli, Neil C Rogers, Erik Sahai, Santiago Zelenay, Caetano Reis e Sousa. Cell 2018
693
7

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, John P Ray, Carl G de Boer, Russell W Jenkins, David J Lieb, Jonathan H Chen, Dennie T Frederick, Michal Barzily-Rokni,[...]. Cell 2018
627
7

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, Nagahiro Minato. Proc Natl Acad Sci U S A 2002
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.